Merck Sharp & Dohme 8-K Merck Announces 2007 Financial Results Reflecting Revenue Growth from Key Products

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2007

EQUITY (INCOME) FROM AFFILIATES (millions of dollars)

	4Q `07			4Q `06			YTD 2007			YTD 2006
MERCK / SCHERING-PLOUGH	$	(537.7	)	$	(360.5	)	$	(1,830.8	)	$	(1,218.6	)
ASTRAZENECA LP		(211.8	)		(181.1	)		(820.1	)		(783.7	)
Other(1)		(46.8	)		(42.6	)		(325.6	)		(292.1	)
TOTAL	$	(796.3	)	$	(584.2	)	$	(2,976.5	)	$	(2,294.4	)

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	4Q `07		4Q `06		YTD 2007		YTD 2006
IVOMEC, HEARTGARD, other avermectins	$	111.7	$	106.7	$	478.4	$	468.7
FRONTLINE, other fipronil		167.2		154.3		1,033.3		886.9
BIOLOGICALS		202.1		165.1		674.9		600.7
Other Animal Health		70.2		63.0		262.2		238.4
TOTAL MERIAL SALES	$	551.2	$	489.1	$	2,448.8	$	2,194.7

Sanofi Pasteur-MSD	4Q `07		4Q `06		YTD 2007		YTD 2006
HEPATITIS VACCINES	$	19.0	$	16.6	$	72.9	$	70.9
VIRAL VACCINES		21.8		30.5		86.8		100.1
Other Vaccines(1)		498.3		287.3		1,278.3		742.9
TOTAL SANOFI PASTEUR-MSD SALES	$	539.1	$	334.4	$	1,438.0	$	913.9

⁽¹⁾ Includes sales ofGardasilof $231.0 million in 4Q 07 and $476.0 million for full year 2007.

Merck / Schering-Plough Collaboration	4Q `07		4Q `06		YTD 2007		YTD 2006
VYTORIN	$	775.9	$	552.9	$	2,779.1	$	1,955.3
ZETIA		678.6		536.1		2,407.1		1,928.8
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,454.5	$	1,089.0	$	5,186.2	$	3,884.1

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q `07			4Q `06			YTD 2007			YTD 2006
INTEREST INCOME	$	(200.2	)	$	(199.7	)	$	(741.1	)	$	(764.3	)
INTEREST EXPENSE		87.1			97.2			384.3			375.1
EXCHANGE GAINS		(14.5	)		(20.5	)		(54.3	)		(25.0	)
MINORITY INTERESTS		29.4			29.9			121.4			120.5
Other, net(1)		665.6			16.0			335.9			(89.0	)
TOTAL	$	567.4		$	(77.1	)	$	46.2		$	(382.7	)

⁽¹⁾ Reflects a civil governmental investigations charge of $671.1 million recorded in fourth quarter 2007. Full year 2007 also reflects the favorable impact of gains on sales of assets and product divestitures, as well as a net gain on the settlements of certain patent disputes.

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2007

NET PRODUCT SALES DETAIL (millions of dollars)

	4Q `07 vs. 4Q `06
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		3	%		891		3	%		329		3	%		563
FOSAMAX		1	%		796		1	%		522		1	%		274
SINGULAIR		20	%		1,154		15	%		796		33	%		358
ZOCOR		-41	%		222		-66	%		55		-23	%		168
Vaccines:
GARDASIL		*			339		87	%		268		*			71
ROTATEQ		*			149		*			142		*			7
ZOSTAVAX		*			85		*			85		N/A			—
OTHER VIRAL VACCINES(1)		42	%		329		45	%		313		7	%		16
HEPATITIS VACCINES		-10	%		60		-13	%		49		6	%		11
OTHER VACCINES		-6	%		125		-24	%		89		*			36
Other Reported Products:
AGGRASTAT		18	%		23		N/A			—		18	%		23
ARCOXIA		14	%		84		N/A			—		14	%		84
CANCIDAS		1	%		134		-59	%		20		35	%		114
COSOPT / TRUSOPT		18	%		212		20	%		96		17	%		116
CRIXIVAN / STOCRIN		-9	%		80		-24	%		5		-8	%		75
EMEND		69	%		61		50	%		38		*			22
INVANZ		30	%		53		17	%		28		51	%		25
JANUVIA		*			252		*			229		*			23
JANUMET		*			44		*			42		*			2
MAXALT		13	%		126		13	%		85		14	%		41
PRIMAXIN		8	%		195		-12	%		51		17	%		144
PROPECIA		9	%		113		6	%		39		11	%		73
PROSCAR		-31	%		83		-82	%		4		-18	%		79
TIMOPTIC / TIMOPTIC XE		-2	%		32		-17	%		2		-1	%		30
VASOTEC / VASERETIC		-8	%		126		N/A			—		-8	%		126
ZOLINZA		96	%		3		91	%		3		N/A			—

* 100% or over
N/A – Not Applicable
⁽¹⁾ – Includes ProQuad, M-M-R II and Varivax.
⁽²⁾ – Includes Isentress $29m.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	4Q '07		% CHG			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES(2)	$	6,243		3	%		-1		1		4
U.S. ($ MM)		3,722		-1	%		-4		3		N/A
Foreign ($ MM)		2,521		10	%		4		-4		9

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
DECEMBER YEAR-TO-DATE
2007

NET PRODUCT SALES DETAIL (millions of dollars)

	DECEMBER YTD `07 vs. DECEMBER YTD `06
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		6	%		3,350		8	%		1,235		5	%		2,115
FOSAMAX		-3	%		3,049		—			1,982		-7	%		1,067
SINGULAIR		19	%		4,266		16	%		2,992		27	%		1,274
ZOCOR		-69	%		876		-90	%		182		-24	%		694
Vaccines:
GARDASIL		*			1,481		*			1,194		*			287
ROTATEQ		*			525		*			499		*			25
ZOSTAVAX		*			236		*			236		N/A			—
OTHER VIRAL VACCINES(1)		64	%		1,347		72	%		1,279		-10	%		68
HEPATITIS VACCINES		13	%		280		16	%		235		-3	%		45
OTHER VACCINES		16	%		410		3	%		302		79	%		108
Other Reported Products:
AGGRASTAT		1	%		87		N/A			—		1	%		87
ARCOXIA		24	%		329		N/A			—		24	%		329
CANCIDAS		1	%		537		-42	%		127		32	%		410
COSOPT / TRUSOPT		13	%		787		14	%		349		12	%		437
CRIXIVAN / STOCRIN		-5	%		310		-17	%		21		-4	%		289
EMEND		56	%		204		40	%		139		*			65
INVANZ		37	%		190		25	%		104		53	%		86
JANUVIA		*			668		*			619		*			48
JANUMET		*			86		*			82		*			4
MAXALT		15	%		467		18	%		314		10	%		153
PRIMAXIN		8	%		764		-1	%		209		12	%		554
PROPECIA		15	%		405		5	%		153		22	%		253
PROSCAR		-34	%		411		-76	%		58		-6	%		353
TIMOPTIC / TIMOPTIC XE		-5	%		120		-14	%		8		-5	%		112
VASOTEC / VASERETIC		-10	%		495		N/A			—		-10	%		495
ZOLINZA		*			11		*			11		N/A			—

* 100% or over
N/A – Not Applicable
⁽¹⁾ – Includes ProQuad, M-M-R II and Varivax.
⁽²⁾ – Includes Isentress $41m.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	FY '07		% CHG			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES(2)	$	24,198		7	%		4		—		2
U.S. ($ MM)		14,691		7	%		4		3		N/A
Foreign ($ MM)		9,507		7	%		5		-3		6